Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | GAA | P10253 | 2/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.56 |
| ▸ | FES | P07332 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.56 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351327 | 1.00 | MAPT (0.80) | MAPTGAACSNK1DKMT2ADCLK1 | |
| SCHEMBL15063116 | 0.94 | MAPT (0.71) | MAPTGAACSNK1DKMT2ADCLK1 | |
| SCHEMBL15062757 | 0.93 | MAPT (0.70) | MAPTGAACSNK1DKMT2ADCLK1 | |
| SCHEMBL15063124 | 0.93 | MAPT (0.69) | MAPTGAACSNK1DKMT2ADCLK1 | |
| SCHEMBL15489029 | 0.92 | MAPT (0.68) | MAPTGAACSNK1DKMT2ADCLK1 | |
| SCHEMBL15112843 | 0.90 | CSNK1D (0.71) | MAPTGAACSNK1DDCLK1FES | |
| SCHEMBL18250793 | 0.89 | MAPT (0.81) | MAPTGAACSNK1DKMT2ADYRK1A | |
| SCHEMBL18250790 | 0.88 | MAPT (0.80) | MAPTGAACSNK1DKMT2ADYRK1A | |
| SCHEMBL15667752 | 0.88 | MAPT (0.80) | MAPTGAACSNK1DKMT2AALOX15 | |
| SCHEMBL15063074 | 0.88 | MAPT (0.80) | MAPTGAACSNK1DKMT2ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410962-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-12018280-B2 | Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes | KYOTO UNIVERSITY (JP) | 2024-06-25 | — | — | US | disclosed |
| WO-2024113354-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024113351-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-20230203447-A1 | Methods of Producing Specialized Cardio-Like Cells from Stem Cells | UNIV EMORY (US) | 2023-06-29 | — | — | US | disclosed |
| US-20160002600-A1 | COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2808383-A1 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO CARDIAC MUSCLE | Kyoto University (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-20140127807-A1 | Method for Promoting Differentiation of Pluripotent Stem Cells into Cardiac Muscle Cells | KYOTO UNIVERSITY (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8658425-B2 | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | KYOTO UNIVERSITY (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658425-B2 | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | KYOTO UNIVERSITY (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658425-B2 | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | KYOTO UNIVERSITY (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2610249-A1 | PLURIPOTENT STEM CELL CARDIOMYOCYTE DIFFERENTIATION-PROMOTING AGENT | Kyoto University (JP) | 2013-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018280-B2 | Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes | TNNI3, MYLK2, TNNT2 | MAPT 695/4885GAA 950/4885CSNK1D 2247/4885 |
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | TNNI3, MYLK2, TNNT2 | MAPT 4471/4885GAA 2914/4885CSNK1D 1539/4885 |
| US-20140127807-A1 | Method for Promoting Differentiation of Pluripotent Stem Cells into Cardiac Muscle Cells | TNNI3, MYLK2, TNNT2 | MAPT 4439/4885GAA 2721/4885CSNK1D 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.